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Tumour-associated antigens (TAA)-specific vaccination requires highly immunogenic reagents capable of inducing cytotoxic T cells
(CTL). Soluble peptides are currently used in clinical applications despite an acknowledged poor immunogenicity. Encapsulation into
liposomes has been suggested to improve the immunogenicity of discrete antigen formulations. We comparatively evaluated the
capacity of HLA-A2.1 restricted Melan-A/MART-1 epitopes in soluble form (S) or following inclusion into sterically stabilised
liposomes (SSL) to be recognised by specific CTL, to stimulate their proliferation and to induce them in healthy donors’ peripheral
blood mononuclear cells (PBMC), as well as in melanoma-derived tumour-infiltrating lymphocytes (TIL). HLA-A2.1
þ, Melan-A/
MART-1-NA-8 melanoma cells served as targets of specific CTL in 51Cr release assays upon pulsing by untreated or human plasma-
treated soluble or SSL-encapsulated Melan-A/MART-1 27–35 (M27–35) or 26–35 (M26–35) epitopes. These reagents were also
used to stimulate CTL proliferation, measured as 3H-thymidine incorporation, in the presence of immature dendritic cells (iDC), as
antigen-presenting cells (APC). Induction of specific CTL upon stimulation with soluble or SSL-encapsulated peptides was attempted
in healthy donors’ PBMC or melanoma-derived TIL, and monitored by 51Cr release assays and tetramer staining. Na-8 cells pulsing
with SSL M27–35 resulted in a five-fold more effective killing by specific CTL as compared with equal amounts of S M27–35.
Encapsulation into SSL also provided a partial (50%) protection of M27–35 from plasma hydrolysis. No specific advantages regarding
M26–35 were detectable in these assays. However, at low epitope concentrations (p100ngml
 1), SSL M26–35 was significantly
more effective in inducing CTL proliferation than S M26–35, in the presence of iDC, as APC. Preincubation with iDC for 6h virtually
abolished the capacity of S M26–35 to stimulate specific CTL proliferation, but only partially affected that of SSL M26–35. Most
importantly, SSL M26–35 was able to enhance the induction of specific CTL in healthy donors PBMC and in melanoma-derived TIL
as compared to S M26–35. Taken together, our data indicate that encapsulation of TAA epitopes into SSL results in effective
immunogenic formulations suitable for clinical use in active specific tumour immunotherapy.
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The identification of a large series of human tumour-associated
antigens (TAA) in the past decade suggests that, upon appropriate
immunisation, cellular responses capable of targeting neoplastic
cells could be induced (Boon and van der Bruggen, 1996; Renkvist
et al, 2001). Although the ‘in vivo’ generation of effective HLA-
class I-restricted cytotoxic T-cell (CTL) responses still represents a
challenge, clinical trials have promptly been designed, taking
advantage of different immunogenic formulations.
Synthetic peptides have been used in the presence or absence of
cytokines or adjuvants in a number of protocols, and their
administration has been shown to result in clinical responses
(Jaeger et al, 1996; Rosenberg et al, 1998; Marchand et al, 1999).
Still, peptides are poor immunogens, characterised by short half-
lives ‘in vitro’ and ‘in vivo’, possibly due to the effects of serum and
cellular peptidases (Amoscato et al, 1998; Brinckerhoff et al, 1999;
Blanchet et al, 2001; Albo et al, 2003), and long immunisation
courses are required before specific responsiveness eventually
becomes evident (Jaeger et al, 1996; Marchand et al, 1999, Coulie
and van der Bruggen, 2003).
Liposomes constructed according to different formulations have
long been used as drug carriers (Langer, 1998; Lasic, 1998) or
vaccine components (Alving et al, 1995; Gluck, 1995; Gregoriadis,
1999; Gregoriadis et al, 1999). Interestingly, liposomes containing
lipopeptides derived from MUC1 human TAA and monopho-
sphoryl lipid A as adjuvant were shown to be able to induce
specific immune responses in vitro (Agrawal et al, 1998).
Sterically stabilised liposomes (SSL, Woodle and Lasic, 1992;
Allen, 1994) characterised by PEG coating display prolonged
bioavailability, but decreased cellular uptake, as compared to
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sconventional liposomes. Interestingly, SSL containing a model
antigenic protein have been shown to induce both class I and class
II restricted immune responses in mice (Ignatius et al, 2000) upon
presentation by professional antigen-presenting cells (APC) such
as dendritic cells (DC).
We constructed SSL containing immunodominant HLA-A2.1
restricted CTL epitopes derived from Melan-A/MART-1 melanoma
TAA (Kawakami et al, 1994; Valmori et al, 1998), and we have
analysed their immunogenicity in vitro in comparison with their
soluble counterpart. We show here that antigenic peptides encapsu-
lated in SSL display a significantly higher capacity to resist plasma
enzymatic hydrolysis, stimulate T-cell proliferation, and to induce
specific cytotoxic T-cell responses than their soluble counterparts.
MATERIALS AND METHODS
Synthetic peptides
Antigenic Melan-A/MART-1 and control (HLA-A2.1 binding, p21
ras derived, Juretic et al, 1996) peptides were produced on a 9050
Millipore peptide synthesiser (Millipore, Volketswil, CH, Switzer-
land) using N-alpha-fluorenylmethoxycarbonylamino-acid penta-
fluorophenyl esters (Juretic et al, 1996). The purity of the reagents
thus produced (495%) was verified by mass spectrometry
(courtesy of Dr S Stevanovic, Tu ¨bingen, Germany).
Liposome production and characterisation
Sterically stabilised liposomes were generated upon solubilisation
in chloroform (HPLC grade, Fluka, Buchs, CH, Switzerland) of
cholesterol, distearylphosphatidylcholine and distearylphosphati-
dylethanolamine-PEG
2000 (all synthetic lipids from Genzyme
Pharmaceuticals, Liestal, CH, Switzerland). The molar ratio used
was 1:0.65 phospholipids to cholesterol. The lipids were then
dried down in a rotatory evaporator to a thin lipid film. Upon
rehydration and mechanical dispersion into a solution of Mart-1/
Melan-A26–35 peptide in PBS (Life Technologies, Paisley, UK),
multilamellar liposomes were formed. Sterically stabilised lipo-
somes batches were then submitted to five cycles of freeze–thaw to
obtain a homogenous suspension and optimise peptide encapsula-
tion. Sizing down of SSL to 100nm small unilamellar vesicles was
achieved by using a LiposoFast extruder (Avestin Inc., Ottawa,
Canada).
Separation of SSL-encapsulated and soluble peptides was
obtained by gel chromatography on Sepharose CL4b columns
(Amersham Pharmacia Biotech, Du ¨bendorf, CH, Switzerland) and
extensive dialysis. Finally, SSL suspensions were filtered for
sterility with a 200nm filter (Orange Scientific, Waterloo,
Belgium). Sterically stabilised liposomes SSL preparations were
stored at 41C in the dark to prevent lipid oxidation.
The size of liposomes in individual SSL batches was tested by
photon correlation spectroscopy using a DynaPro-801 molecular
sizing instrument equipped with a temperature-controlled micro-
sampler (Protein Solutions, Charlotteville, SC, USA). The uni-
lamellarity of the liposomes was verified by electron microscopy
(negative staining technique). Quantification of SSL-encapsulated
peptides was performed by fluorescamine assay (Udenfriend et al,
1972): fluorescence was measured at 405nm absorbance and
475nm emission wavelengths. No fluorescence was recorded on
empty SSL or on phospholipids in solution.
SSL preparations were negative (o10pgml
 1) when tested for
endotoxin contamination by chromogenic Limulus Amebocyte
lysate assay (Charles River, Charleston, SC, USA).
Cellular reagents and culture conditions
Healthy donors’ or patients’ PBMC were obtained from hepar-
inised venous blood samples or buffy coat preparations (Blut-
spendezentrum, Basel, Switzerland) upon Ficoll (Lymphoprep,
Nycomed, Oslo, Norway) centrifugation followed by two washes
with PBS. Cells were cultured in RPMI1640 medium supplemented
with Ciproxin (Bayer, Zurich, Switzerland, 10mgml
 1), glutamine
(2mM), sodium pyruvate, nonessential amino acids, HEPES buffer
(GIBCO, Paisley, UK all 1mM) and 5% heat-inactivated human AB
serum, thereafter referred to as complete AB medium. Cytotoxic T-
cells clones were generated from melanoma patients’ PBMC, as
previously detailed (Noppen et al, 2000), maintained in culture in
complete medium supplemented with 200Uml
 1 of recombinant
IL-2 (rIL-2, Hoffman-LaRoche, Basel, Switzerland) and periodi-
cally re-stimulated with purified PHA (1mgml
 1, Abbott, Baar,
Switzerland) in the presence of irradiated allogenic PBMC.
CD14
þ cells were isolated with magnetic beads (Miltenyi,
Bergisch-Gladbach, Germany). Immature dendritic cells were
prepared as previously outlined (Remmel et al, 2001) from
positively sorted CD14
þ cells upon 5–7 days culture in RPMI
1640 supplemented with 10% FCS, ciproxin, glutamine, sodium
pyruvate, nonessential amino acids and HEPES buffer (complete
FCS medium), in the presence of GM-CSF (50ngml
 1, Novartis,
Basel, CH, Switzerland) and IL-4 (1000Uml
 1, courtesy of Dr
Lanzavecchia, Bellinzona, CH, Switzerland). These iDC displayed
the typical CD14
 , CD1a
þ phenotype.
Functional assays
Cytotoxic activity was tested against Cr
51-labelled and peptide-
pulsed Na-8 cells (courtesy of Dr F Jotereau, Nantes, France) at
1000 cells well
 1, in the presence of a 100-fold excess of unlabelled
K562 cells to quench the background NK-like activity. For each
culture, cytotoxicity assays were performed by using, as targets,
cells pulsed in the presence of specific or control peptides or SSL
preparations. Percent killing was calculated according to the
standard formula.
Proliferation of MART-1/Melan-A-specific HLA-A2.1-restricted
CTL clones was tested as follows. Cells (1 10
5 in 100mlo f
complete AB medium) were seeded in triplicates in flat-bottom,
96-well plates. As APC, 5 10
4 purified, HLA-A2.1-matched, iDC
cells were added. Antigenic preparations were then supplemented
at the concentrations indicated. In dedicated experiments, APC
were preincubated for varying time lengths in the presence of
immunogenic preparations and CTL were subsequently added. All
cultures were prolonged for 3 days, including an overnight
incubation in the presence of
3H-thymidine (1mCiwell
 1, Amer-
sham, Little Chalfont, UK). Cultures were then harvested and
incorporated radioactivity was counted on a Betaplate counter
(LKB Wallac, Turku, Finland).
Generation of peptide-specific CD8
þ T lymphocytes from
healthy donors
PBMC from HLA-A2.1-positive healthy donors were cultured in
complete medium at 10
6cellsml
 1 concentration in the presence of
antigenic or control peptides (10mgml
 1) encapsulated into SSL or
in solution. After 7 days of culture, cells were supplemented with
rIL-2 at 20Uml
 1 concentration. On day 10, cultures were
restimulated with autologous irradiated EBV-transformed lym-
phoblastoid cell lines (EBV-LCL) in the presence of the above
listed materials and rIL-2 at the same concentrations as above.
Restimulations were performed on a weekly basis, whereas rIL-2
(20Uml
 1) was added to the cultures twice per week.
Generation of tumour-infiltrating lymphocytes from
melanoma biopsies
Surgical biopsies were obtained upon informed consent from
melanoma patients undergoing staging procedures and single-cell
suspensions were mechanically obtained. Cells were cultured in
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scomplete AB medium supplemented with rIL-2 at 200IUml
 1 in
24-well culture plates previously precoated with anti-CD3 (cour-
tesy of Dr Lanzavecchia, Bellinzona, Switzerland) and anti-CD28
(Becton Dickinson, San Jose, CA, USA) monoclonal antibodies
(1mgml
 1). After a 2-weeks culture, over 95% of cells were CD3
þ
lymphocytes (Spagnoli et al, 1995).
CTL precursor frequency
Magnetic beads (Miltenyi Biotech, Bergisch Gladbach, Germany)
purified CD8
þ TIL were resuspended in complete AB medium and
seeded in 96 round-bottom wells plates (one plate for each S- or
SSL-encapsulated antigen concentration) at different cell numbers
(30.000, 15.000, 7.500 per well, 28 replicates for each). Autologous
EBV-LCL were pulsed for 3h with 20, 2 or 0.2mgml
 1 concentra-
tions of S- or SSL-encapsulated M26–35, together with 5mgml
 1
b2-microglobulin (Sigma, St Louis, MO, USA), irradiated and
added to specific limiting dilution analysis (LDA) plates at 5000
cellswell
 1. rIL-2 was added on days 4,5,6 (20Uml
 1 final
concentration). On day 8, 2mgml
 1 of peptide in the same form
used on day 1 was added together with rIL-2 (100Uml
 1 final
concentration). rIL-2 was again added on day 11 at 100Uml
 1
final concentration. On day 15, each well was split into two and
cytotoxic activity was tested by using as target cells Na-8 pulsed
with M26–35 or a control peptide. Culture wells displaying X25%
specific cytotoxicity were considered positive and CTL precursor
frequency was calculated as previously described (Chaux et al,
1998; Oertli et al, 2002).
CTL tetramer staining
TIL from bulk cultures stimulated exactly according to the LDA
protocol were stained on day 15 with HLA-A0201 tetramer-PE
complex including M27–35 (Proimmune, Oxford, UK) and anti-
human CD8-FITC (Becton Dickinson, San Jose, CA, USA). After
45min incubation on ice, cells were washed with PBS and analysed
by flow cytometry. Data were reported as percentages of tetramer-
positive CD8
þ T cells and mean fluorescence intensities (MFI).
Positivity thresholds were established at MFI levels 10-fold higher
than in unstained cells (Lee et al, 1999).
RESULTS
Construction of SSL antigenic preparations: size and
epitope content stability
About 20% of the initial peptide input (19.276.5%) was
encapsulated in SSL in the different batches used throughout this
work. The stability of SSL in terms of size and peptide content was
assessed at 1, 3 and 6 months after synthesis. Upon repeated
photon correlation spectroscopy, different batches of SSL stored at
þ41C in PBS showed nonsignificant increases in their mean
diameter at 6 months only (105 vs 85nm mean diameter). Peptide
content remained quantitatively stable within the indicated time
frame.
Encapsulation of M27–35 peptide into SSL improves
immunorecognition by specific cytotoxic T cells
The capacity of SSL-based antigenic preparations to sensitise
target cells to the killing by HLA-A2.1-restricted cytotoxic T cells
recognising both M26–35 and M27–35 was first tested in
comparison with the corresponding soluble peptides. NA-8,
HLA-A2.1
þ melanoma cells not expressing the antigen under
investigation were preincubated in the presence of graded amounts
of target or control peptides in soluble form or included in SSL.
Maximal killing by specific CTL was detectable upon target
preincubation in the presence of 0.4mgml
 1 of soluble M27–35,
but significantly lower (0.016–0.001mgml
 1) concentrations of
M26–35. Encapsulation into SSL did not modulate the targeting
capacity of M26–35. In contrast, inclusion of M27–35 in SSL
resulted in a significant improvement of the targeting capacity of
the synthetic epitope, with maximal killing being observed at
0.08mgml
 1 nominal peptide concentration.
Encapsulation into SSL protects M27–35 from the action of
plasma peptidases
Epitope stability in the presence of human serum or plasma has
previously been investigated (Brinckerhoff et al, 1999; Blanchet
et al, 2001). We asked whether encapsulation into SSL could
protect peptides from plasma enzyme degradation, as indirectly
measured by comparing their capacity to sensitise target cells to
the killing by specific CTL. In agreement with previous reports
(Blanchet et al, 2001), M27–35 peptide was rapidly degraded (80%
loss of activity) within 45min of preincubation in the presence of
human plasma. Encapsulation of M27–35 into SSL appeared to
effectively protect the epitope from enzymatic degradation, with
loss of activity in those same conditions limited to 30%. On the
other hand, M26–35, either in solution or included into SSL,
appeared to be more resistant to hydrolysis with no loss of activity
(o5%) being detectable upon 45min incubation in the presence of
plasma.
DC as presenters of antigens encapsulated in SSL
Taken together, the above data clearly indicated that encapsulation
into SSL improved immunorecognition of M27–35, possibly by
protecting the synthetic epitope from enzymatic degradation. By
contrast, no evident advantage appeared to be provided by M26–
35 inclusion into SSL.
However, while T-cell receptor-mediated immunorecognition
represents an obvious prerequisite for the induction of specific
immune responses, the efficacy of vaccination procedures is
critically dependent on the expansion of specific T cells. In
particular, antigen-stimulated T-cell proliferation not only re-
quires adequate costimulation, but also an increased density of
MHC/peptide complexes on APC, as compared to mere targeting
of cytotoxic activity (Schild et al, 1990; Gervois et al, 1996).
Immunogenic class I restricted peptides are usually injected
intradermally for vaccination purposes (Jaeger et al, 1996;
Rosenberg et al, 1998; Marchand et al, 1999). The main APC type
in this tissue is represented by Langerhans cells (LC), iDC that,
upon antigen uptake and maturation traffick to lymph nodes, are
able to activate both naive and memory T cells (Bell et al, 1999;
Lanzavecchia and Sallusto, 2001) (Figures 1, 2).
A convenient ‘in vitro’ model to explore the immunobiology of
LC is represented by iDC (Romani and Schuler, 1992) obtained by
culturing CD14
þ PBMC in the presence of IL-4 and GM-CSF
(Sallusto and Lanzavecchia, 1994).
HLA-A2.1 iDC were used as APC to present M26–35 in either
SSL-encapsulated or soluble form to specific CTL clones. When
antigenic preparations were added simultaneously together with
iDC to responding T cells, inclusion into SSL determined a
significant enhancement of M27–35 epitope presentation, as
compared to soluble peptide (Figure 3A). This effect was mainly
observed at low nominal epitope concentrations.
Time-course experiment revealed the adverse effect of the
preincubation of either antigenic preparations in the presence of
iDC on the presentation to CTL, as detectable by proliferation
(Figure 3B). Epitope degradation was conspicuously detectable at a
1mgml
 1 nominal antigen concentration. Remarkably, regarding
peptides in solution, at 6h a 480% inhibition was observed, as
compared to 50% for reagents contained into SSL. Similar results
were obtained when CD14
þ monocytes were used as APC (data
not shown).
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sThese effects could be partially circumvented by increases in
antigen concentrations. Thus, when the epitopes were adminis-
tered at 8mgml
 1, either preparation induced identical CTL
proliferation, with 3H-thymidine incorporation induced upon a
6h preincubation ranging around 50% of values detectable in the
presence of untreated antigen formulations.
SSL induce specific CTL in healthy donors’ PBMC
The capacity of M26–35 peptide in either SSL-encapsulated or
soluble form to induce specific CTL was comparatively evaluated
by using PBMC from healthy donors as responder cells. In two (out
of three) donors tested, following repeated (two to three)
stimulations in the presence of autologous EBV-LCL, specific
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Figure 1 Immunorecognition of Melan-A/MART-1 epitopes by specific
CTL. HLA-A2.1-positive, Melan-A/MART-1-negative NA-8 cells were 51Cr
labelled and incubated for 2h in the presence of graded amounts of Melan-
A/MART-1 27–35 (M27–35, panel (A)) or 26–35 (M26–35, panel (B))
epitopes or control peptides in soluble form (SC) or encapsulated into
sterically stabilised liposomes (SSL C). Cells were then washed and cultured
for 4h in the presence of a specific HLA-A2.1-restricted cytotoxic T-cell
clone at 5:1 effector target ratio. Supernatants were then harvested and
51Cr release was measured by a gamma counter. Data are reported as
mean % specific target cell lysis from triplicate wells. Standard deviations,
never exceeding 10% of the reported values, were omitted.
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Figure 2 Antigenic peptide degradation in the presence of human
plasma. Melan-A/MART-1 27–35 (M27–35, 1mgml
 1) or 26–35 (M26–
35, 8ngml
 1) peptides in soluble form (S) or encapsulated into SSL were
incubated for the indicated times at 371C in the presence of undiluted
human plasma. The different preparations were then used to pulse 51Cr-
labelled Na-8 cells for 2h. These were cocultured for 4h in the presence of
a specific HLA-A2.1-restricted cytotoxic T-cell clone at 5:1 effector target
ratio in triplicate samples. Supernatants were then harvested and 51Cr
release was measured by a gamma counter. Data are reported as % of the
cytotoxic activity detected in the presence of the corresponding untreated
M27–35 or 26–35 preparations. Standard deviations, never exceeding
10% of the reported values, were omitted.
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Figure 3 Induction of specific CTL proliferation by Melan-A/MART-1
26–35 peptide: iDC as antigen-presenting cells. (A) Cells from a Melan-A/
MART-1-specific, HLA-A2.1-restricted CTL clone were cultured in the
presence of irradiated, HLA-A2.1-matched, CD14
 /CD1a
þ immature,
monocyte-derived dendritic cells, and the indicated concentrations of
Melan-A/MART-1 26–35 or control peptides in soluble form (shaded and
white columns, respectively) or contained into SSL (black and striped
columns, respectively). Proliferation of triplicate wells was assessed by 3H-
thymidine on day three of culture. (B) HLA-A2.1-positive monocyte-
derived CD14
 /CD1a
þ iDC were cultured for 3 or 6h (middle and lower
panels, respectively) in the presence of Melan-A/MART-1 26–35 or
control peptides in soluble form (shaded and white columns, respectively)
or contained into SSL (black and striped columns, respectively) at the
indicated concentrations. T cells from a specific CTL clone were then
added. Data reported in the upper panel refer to cultures where iDC, CTL
and immunogenic materials were simultaneously added without preincuba-
tion steps. In all cases, 3H-thymidine incorporation of triplicate wells was
measured after 3 days culture.
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scytotoxic activity could indeed be generated. Remarkably, in both
donors, CTL were only detectable in cultures stimulated with SSL
preparations and no specific killing was observed upon soluble
peptide stimulation. Figure 4 reports data from these experiments.
As expectable (Oertli et al, 2002) M26–35-specific CTL were also
able to kill HLA-A2.1
þ melanoma cells expressing the TAA under
investigation (data not shown).
SSL induce specific CTL in melanoma derived tumour-
infiltrating lymphocytes
We then comparatively tested the capacity of S or SSL M26–35 to
induce specific CTL from tumour-infiltrating lymphocytes (TIL)
from melanoma patients. In order to allow quantitative evalua-
tions, we used different concentrations of immunogens and a
limiting dilution analysis (LDA) setting to estimate specific CTL
precursors’ (CTLp) frequencies.
Specific CTL generation was obtained by short-term culture
(Oertli et al, 2002) in one out of two TIL preparations. At
20mgml
 1 antigen concentration SSL or S M26–35 peptide were
equally effective, with a CTLp of about 20/10
6. On the other hand,
at 2mgml
 1 antigen concentration, while SSL M26–35 peptide
retained its full immunogenic capacity, S M26–35 peptide was
virtually unable to induce specific responsiveness. Finally, at
0.2mgml
 1 antigen concentration, both formulations were equally
ineffective (Figure 5).
On tetramer staining analysis, stimulation with 0.2mgml
 1
antigen concentration did not result in detectable expansion of
tetramer-positive cells. Upon stimulation with a 2mgml
 1 antigen
concentration of SSL M26–35, 4.8% of cells were tetramer positive,
as compared to 3.4% upon S M26–35 induction (Figure 5). Finally,
20mgml
 1 antigen concentrations of either SSL or S M26–35
peptide induced similar percentages of tetramer-positive CD8
þ
cells (6.2 and 6.3%, respectively). Remarkably, at both antigen
concentrations, MFI values were higher in cultures stimulated with
SSL as compared to S M26–35 peptide (189 vs 120 at 20mgml
 1
and 144 vs 122 at 2mgml
 1).
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Figure 4 Induction of Melan-A/MART-1 specific CTL by synthetic
peptides encapsulated into SSL. Healthy donor’s PBMC were cultured for 1
week in the presence of Melan-A/MART-1 26–35 or control peptides at
10mgml
 1 in soluble form (shaded symbols) or encapsulated into SSL
(black symbols). rIL-2 (20Uml
 1) was then added and cultures were
restimulated on day 10 and weekly thereafter with the same materials in
the presence of autologous irradiated EBV-LCL and rIL-2. Cytotoxic activity
was tested by using as targets HLA-A2.1-positive, Melan-A/MART-1-
negative cells upon pulsing with soluble M26–35 (circles) or control
peptide (squares). Data from two donors (panels (A) and (B)) are shown.
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Figure 5 Induction of specific CTL by S M26–35 and SSL M26–35 in
melanoma-derived TIL. Panel (A): CD8
þ melanoma-derived TIL were
stimulated in an LDA setting with decreasing amounts of S M26–35 or SSL
M26–35 antigens. cytotoxic T-cells precursor frequencies are expressed as
the number of specific effectors per 10
6 CD8
þ cells. Panel (B): CD8
þ
melanoma-derived TIL stimulated in bulk cultures in the presence of the
indicated antigen formulations and concentrations were stained with FITC-
labelled anti-CD8 and PE-labelled M27–35 tetramers, as described in
‘Materials and methods’. Percentages of tetramer-positive CD8
þ cells and
the respective MFI are reported.
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Following the molecular characterisation of human TAA, active
specific immunotherapy is being increasingly used in cancer
treatment. Critical to this purpose is the development of vaccine
formulations endowed with high immunogenicity. Indeed, a large
majority of human TAA are also expressed to some extent in
physiological conditions (Renkvist et al, 2001) and immune
tolerance towards them is likely to exist. Furthermore, advanced
stage tumour patients frequently present ill-defined impairments
of immune responsiveness. A number of reports indicate that,
irrespective of discrete vaccination procedures, repeated immuni-
sation courses are required in order to obtain detectable specific
stimulation, and such responsiveness is frequently not sustained in
time (Jaeger et al, 1996; Marchand et al, 1999; Thurner et al, 1999).
Most active specific immunotherapies currently rely on the in
vivo administration (Jaeger et al, 1996; Rosenberg et al, 1998;
Marchand et al, 1999) or the ex vivo pulsing of APC prior to re-
infusion, with synthetic peptides (Nestle et al, 1998; Thurner et al,
1999). These reagents bind empty HLA molecules present in low
numbers on the surface of APC. However, they are also
concomitantly subject to degradation by soluble or cell mem-
brane-associated peptidases (Amoscato et al, 1998; Brinckerhoff
et al, 1999; Blanchet et al, 2001; Albo et al, 2003). As a result, they
represent poor immunogens.
In this context, since persistence of the antigen (Zinkernagel and
Hengartner, 2001) is emerging as a critical factor for the induction
of specific immune responses, the respective bio-availabilities of
different vaccine formulations assume crucial relevance.
Liposomes have long been used to carry drugs, proteins,
peptides or, more recently, DNA (Alving et al, 1995; Lasic, 1998;
Gregoriadis, 1999), and to protect them from degradation.
Liposome based vaccine preparations specific for infectious
agents have been successfully tested (Gluck, 1995). In
particular, induction of CTL by liposome-carrying antigens has
been the subject of a number of reports on animal models
(Ignatius et al, 2000; Ludewig et al, 2001), but there is a
conspicuous paucity of data regarding the effects in humans
(Agrawal et al, 1998).
Based on this background, we have explored the possibility of
constructing innovative vaccine formulations for clinical tumour
immunotherapy, by taking advantage of well-described (Kawakami
et al, 1994; Valmori et al, 1998) HLA-A2.1-restricted peptides from
the immunodominant Melan-A/MART-1 melanoma TAA and
liposome technology. Considering the peculiarity of tumour-
specific immune response (Zinkernagel, 2001), we have focused
on liposomes endowed with increased bioavailability.
Sterically stabilised liposomes are characterised by long
persistence in biological fluids. As a drawback, they show reduced
cellular uptake, in comparison to conventional formulations,
possibly related to inhibition of the interaction with cell surfaces
by the steric PEG coating (Allen, 1994).
We show here that SSL containing Melan-A/MART-1 peptides
represent significantly more effective immunogenic formulations
than their soluble counterparts. Regarding M27–35, their higher
efficiency was already evident in immunorecognition assays by
specific CTL. Furthermore, SSL could partially protect M27–35
from plasma hydrolysis.
On the other hand, M26–35 is known to be more immunogenic
that M27–35 (Valmori et al, 1998) and more resistant to plasma
peptidases (Blanchet et al, 2001). In this respect, SSL encapsulation
did not provide any further advantage.
The effectiveness of vaccination procedures, however, critically
depends on the expansion of specific T cells. Cytotoxic T-cells
proliferation is characterised by more stringent molecular
requirements, as compared to mere T-cell receptor-mediated
target killing (Schild et al, 1990; Gervois et al, 1996). Not only
costimulation is mandatory, but also higher MHC/peptide
densities on APC are required.
This report clearly indicates that M26–35 encapsulation into
SSL provides a significant advantage over its soluble counterpart in
CTL proliferation assays, particularly when limiting amounts of
antigen were used or prolonged preincubations in the presence of
serum-containing medium and APC were applied.
These data are consistent with those recently reported by
Ludewig et al (2001) in a defined mouse model, indicating that
presentation of exogenous antigen to self-reactive CTL is markedly
inefficient due to the rapid turnover on APC. Due to the short
persistence of exogenous epitope on APC, specific CTL stimulation
can only be achieved in the presence of high synthetic peptide
concentrations. A major role in epitope degradation could be
played by peptidases associated to APC (Amoscato et al, 1998;
Albo et al, 2003).
It should be noted that the sensitivity of individual epitopes to
enzymatic hydrolysis is highly variable. In this context, encapsula-
tion of degradation-sensitive peptides into SSL is likely to provide
enhanced immunogenicity.
Accordingly, M26–35 peptide encapsulated into SSL
efficiently induced specific CTL in PBMC from healthy donors,
following relatively few (two to three) restimulation courses. In
our hands, effector cell induction could actually be induced
by soluble peptides as well (Valmori et al, 1998; Blanchet et al,
2001), but usually required longer culture times (44 restimula-
tions).
The data obtained by using melanoma TIL as responder cells
further support the concept of an enhanced immunogenicity of
SSL M26–35, in comparison to S M26–35, as detected by CTLp
frequency analysis and tetramer staining. In the latter assays, MFI,
an indicator of functional antigen receptor avidity (Yee et al,
1999), was also increased in SSL M26–35-, as compared to S M26–
35-stimulated cultures.
Taken together, our data suggest that SSL containing antigenic
peptides could represent an effective alternative to soluble
synthetic epitopes, both for direct in vivo administration and for
ex vivo pulsing. Lack of intrinsic immunogenicity, favouring
repeated use, low price and the possibility to easily manufacture
SSL under GMP conditions concur in supporting their clinical
applications.
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